Liao Tien You, Tzeng Wen-Yu, Wu Hsin-Hua, Cherng Chianfang G, Wang Ching-Yi, Hu Sherry S-J, Yu Lung
Institute of Behavioral Medicine, National Cheng Kung University College of Medicine, 1 University Rd., Tainan, 70101, Taiwan, ROC.
Department of Health Psychology, Chang Jung Christian University, Tainan, 71101, Taiwan, ROC.
Psychopharmacology (Berl). 2016 Apr;233(8):1455-65. doi: 10.1007/s00213-016-4251-8. Epub 2016 Mar 10.
Since brain proteins such as protein kinase C (PKC), brain-derived neurotrophic factor (BDNF), and mammalian target of rapamycin (mTOR) are involved in the establishment and maintenance of psychostimulant memory, we sought to determine if systemic treatment with rottlerin, a natural compound affecting all these proteins, may modulate stimulant-supported memory.
Stimulant-induced conditioned place preference (CPP) was used in modeling stimulant-supported memory.
Three cocaine (10 mg/kg; COC) or three methamphetamine (1 mg/kg; MA) conditioning trials reliably established the drug-induced CPP in male C57BL/6 mice. An intra-peritoneal rottlerin injection (5 mg/kg) at least 24 h prior to the first COC or first MA conditioning trial prevented the establishment of CPP. Following the establishment of the COC- or MA-induced CPP, saline conditioning trial was used to extinguish the CPP. Rottlerin (5 mg/kg, intra-peritoneal (i.p.)) administered 20 h prior to the first saline conditioning trial diminished subsequent drug- and stressor-primed reinstatement of the extinguished CPP. Rottlerin (5 mg/kg, i.p.) produced a fast-onset and long-lasting increase in hippocampal BDNF levels. However, treatment with a BDNF tropomyosin receptor kinase B (TrkB) receptor antagonist, K252a (5 μg/kg), did not affect rottlerin's suppressing effect on COC-induced CPP and treatment with 7,8-dihydroxyflavone (10 mg/kg x 6, 7,8-DHF), a selective TrkB agonist, prior to each conditioning trial did not affect COC-induced CPP.
These results suggest that systemic rottlerin treatment may impair the formation of COC- and MA-supported memory. Importantly, such a treatment may advance our understanding of the underlying mechanism through which extinction training resulted in the "forgetting" of the COC- and MA-supported memory.
由于诸如蛋白激酶C(PKC)、脑源性神经营养因子(BDNF)和雷帕霉素哺乳动物靶点(mTOR)等脑蛋白参与了精神兴奋剂记忆的建立和维持,我们试图确定用rottlerin(一种影响所有这些蛋白的天然化合物)进行全身治疗是否可以调节兴奋剂支持的记忆。
使用兴奋剂诱导的条件性位置偏爱(CPP)来模拟兴奋剂支持的记忆。
三次可卡因(10毫克/千克;COC)或三次甲基苯丙胺(1毫克/千克;MA)条件性试验在雄性C57BL/6小鼠中可靠地建立了药物诱导的CPP。在第一次COC或第一次MA条件性试验前至少24小时腹腔注射rottlerin(5毫克/千克)可阻止CPP的建立。在建立COC或MA诱导的CPP后,使用生理盐水条件性试验来消除CPP。在第一次生理盐水条件性试验前20小时给予rottlerin(5毫克/千克,腹腔注射(i.p.))可减少随后药物和应激源引发的消退后CPP的恢复。Rottlerin(5毫克/千克,i.p.)使海马BDNF水平快速升高且持续时间长。然而,用BDNF原肌球蛋白受体激酶B(TrkB)受体拮抗剂K252a(5微克/千克)治疗并不影响rottlerin对COC诱导的CPP的抑制作用,并且在每次条件性试验前用选择性TrkB激动剂7,8-二羟基黄酮(10毫克/千克×6,7,8-DHF)治疗并不影响COC诱导的CPP。
这些结果表明全身rottlerin治疗可能损害COC和MA支持的记忆的形成。重要的是,这种治疗可能增进我们对消退训练导致COC和MA支持的记忆“遗忘”的潜在机制的理解。